-
公开(公告)号：US08882741B2
公开(公告)日：2014-11-11
申请号：US13460219
申请日：2012-04-30
Applicant: James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
Inventor： James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
CPC classification number: A61M5/31525 , A61B5/0002 , A61B5/14532 , A61B5/1486 , A61B5/14865 , A61B5/4839 , A61B2560/0443 , A61M5/1723 , A61M11/00 , A61M15/0001 , A61M2005/1726 , A61M2205/18 , A61M2205/3303 , A61M2205/502 , A61M2205/52 , A61M2230/201 , G06F19/00 , G06F19/3468 , G16H20/17 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
Abstract translation: 提供了用于集成包括接收器，药物输送装置和任选的单点葡萄糖监测器的连续葡萄糖传感器的系统和方法。 手动集成提供了用户（例如，患者或医生）手动选择数量，类型和/或递送时间的设备之间的物理关联。 设备的半自动化集成包括集成，其中集成组件之间的可操作连接有助于用户（例如患者或医生）在选择，输入，计算或验证葡萄糖值的药物递送量，类型或时间 例如，通过将数据发送到另一个组件，从而减少所需的用户输入量。 设备之间的自动集成包括集成，其中集成组件之间的可操作连接提供对系统的完全控制，而不需要用户交互。
-
公开(公告)号：US08845674B2
公开(公告)日：2014-09-30
申请号：US13453790
申请日：2012-04-23
Applicant: Mark C. Brister , Nelson Quintana , Kaushik A. Patel , Neil R. Drake , Antonio C. Llevares , Dubravka Markovic , Andrew P. Rasdal , Amy D. L. VandenBerg
Inventor： Mark C. Brister , Nelson Quintana , Kaushik A. Patel , Neil R. Drake , Antonio C. Llevares , Dubravka Markovic , Andrew P. Rasdal , Amy D. L. VandenBerg
CPC classification number: A61F5/003 , A61B17/1204 , A61B17/12099 , A61B90/39 , A61B2090/3966 , A61F5/0036 , A61F5/0073 , A61F5/0083 , A61L31/088 , A61L31/10 , A61L2400/16 , A61L2420/02 , A61L2420/08 , A61M25/10185 , A61M25/1027 , A61M25/1029 , A61M31/002 , A61M2025/1031 , A61M2025/105 , Y10T156/1051
Abstract: An implant configured for ingestion by a patient. After the implant has been swallowed by the patient and is disposed within the target location, e.g. the patient's stomach, an inflation subcomponent causes the implant to expand from a compact delivery state to an expanded, volume-occupying, deployed state. In the deployed state the implant creates a sensation of satiety in the patient stomach and thereby aids in limiting food intake and obesity. After a predetermined time a deflation subcomponent is actuated and the implant reduces in size so as to allow it to pass through the remainder of the patient's digestive track. The device may further incorporate tracking and visualization subcomponents, as well as pharmaceutical delivery subcomponents.
Abstract translation: 构造成用于由患者摄取的植入物。 在植入物被患者吞咽之后并且被放置在目标位置内，例如， 患者的胃，通气子部件导致植入物从紧凑的递送状态扩展到膨胀的体积占据部署状态。 在部署状态下，植入物在患者胃中产生饱腹感，从而有助于限制食物摄入和肥胖。 在预定时间之后，促使放气次级组件被移动并且植入物的尺寸减小，以便允许其通过病人消化道的其余部分。 该装置还可以包括跟踪和可视化子组件以及药物递送子组件。
-
公开(公告)号：US20120238852A1
公开(公告)日：2012-09-20
申请号：US13460365
申请日：2012-04-30
Applicant: James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
Inventor： James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
CPC classification number: A61M5/31525 , A61B5/0002 , A61B5/14532 , A61B5/1486 , A61B5/14865 , A61B5/4839 , A61B2560/0443 , A61M5/1723 , A61M11/00 , A61M15/0001 , A61M2005/1726 , A61M2205/18 , A61M2205/3303 , A61M2205/502 , A61M2205/52 , A61M2230/201 , G06F19/00 , G06F19/3468 , G16H20/17 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
-
公开(公告)号：US20120190953A1
公开(公告)日：2012-07-26
申请号：US13436534
申请日：2012-03-30
Applicant: James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
Inventor： James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
IPC: A61B5/145
CPC classification number: A61M5/31525 , A61B5/0002 , A61B5/14532 , A61B5/1486 , A61B5/14865 , A61B5/4839 , A61B2560/0443 , A61M5/1723 , A61M11/00 , A61M15/0001 , A61M2005/1726 , A61M2205/18 , A61M2205/3303 , A61M2205/502 , A61M2205/52 , A61M2230/201 , G06F19/3468 , G16H20/17 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
-
公开(公告)号：US08202291B1
公开(公告)日：2012-06-19
申请号：US13069265
申请日：2011-03-22
Applicant: Mark C. Brister , Andrew P. Rasdal , Neil R. Drake , Matthew S. Lake , Dubravka Markovic , Amy D. L. VandenBerg , Antonio C. Llevares , Josefina Nider
Inventor： Mark C. Brister , Andrew P. Rasdal , Neil R. Drake , Matthew S. Lake , Dubravka Markovic , Amy D. L. VandenBerg , Antonio C. Llevares , Josefina Nider
IPC: A61M29/00
CPC classification number: A61M29/00 , A61F5/0013 , A61F5/003 , A61F5/0036 , A61F5/0073 , A61F5/0076 , A61M25/10185
Abstract: Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided. The intragastric devices include an intragastric balloon comprising an initial fill gas comprising an inert gas and CO2, a valve system, and a polymeric wall having, under conditions of an in vivo gastric environment, a permeability to CO2 of more than 10 cc/m2/day, such that a rate and an amount of diffusion of CO2 from the in vivo gastric environment into a lumen of the balloon through the polymeric wall is controlled, at least in part, by a concentration of the inert gas and a concentration of CO2 in the initial fill gas, wherein the concentration of CO2 in the initial fill gas is similar to gastric pCO2.
Abstract translation: 提供了治疗肥胖症的装置和方法。 更具体地，提供了胃内装置及其制造，部署，充气，监测和检索方法。 胃内装置包括胃内气囊，其包括包含惰性气体和CO 2的初始填充气体，阀系统和聚合物壁，其在体内胃环境条件下具有大于10cc / m 2 / 天，从而至少部分地通过惰性气体的浓度和二氧化碳的浓度来控制CO 2从体内胃环境扩散通过聚合物壁的球囊腔的速率和量 初始填充气体，其中初始填充气体中的CO 2浓度类似于胃pCO 2。
-
Patent Agency Ranking
公开(公告)号：US20090299276A1
公开(公告)日：2009-12-03
申请号：US12536852
申请日：2009-08-06
Applicant: James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
Inventor： James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv U. Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
CPC classification number: A61M5/31525 , A61B5/0002 , A61B5/14532 , A61B5/1486 , A61B5/14865 , A61B5/4839 , A61B2560/0443 , A61M5/1723 , A61M11/00 , A61M15/0001 , A61M2005/1726 , A61M2205/18 , A61M2205/3303 , A61M2205/502 , A61M2205/52 , A61M2230/201 , G06F19/00 , G06F19/3468 , G16H20/17 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
Abstract translation: 提供了用于集成包括接收器，药物输送装置和任选的单点葡萄糖监测器的连续葡萄糖传感器的系统和方法。 手动集成提供了用户（例如，患者或医生）手动选择数量，类型和/或递送时间的设备之间的物理关联。 设备的半自动化集成包括集成，其中集成组件之间的可操作连接有助于用户（例如患者或医生）在选择，输入，计算或验证葡萄糖值的药物递送量，类型或时间 例如，通过将数据发送到另一个组件，从而减少所需的用户输入量。 设备之间的自动集成包括集成，其中集成组件之间的可操作连接提供对系统的完全控制，而不需要用户交互。
-
公开(公告)号：US20080228051A1
公开(公告)日：2008-09-18
申请号：US12037812
申请日：2008-02-26
Applicant: Mark C. Shults , James H. Brauker , Victoria Carr-Brendel , Mark A. Tapsak , Dubravka Markovic , Stuart J. Updike , Rathbun K. Rhodes
Inventor： Mark C. Shults , James H. Brauker , Victoria Carr-Brendel , Mark A. Tapsak , Dubravka Markovic , Stuart J. Updike , Rathbun K. Rhodes
IPC: A61B5/145
CPC classification number: A61L31/10 , A61B5/14532 , A61B5/14865 , A61B5/1495 , A61L31/14 , A61L31/146 , A61L31/16 , A61L2300/00 , B33Y80/00 , C12Q1/006
Abstract: An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.
-
公开(公告)号：US20060204536A1
公开(公告)日：2006-09-14
申请号：US11416734
申请日：2006-05-03
Applicant: Mark Shults , James Brauker , Victoria Carr-Brendel , Mark Tapsak , Dubravka Markovic
Inventor： Mark Shults , James Brauker , Victoria Carr-Brendel , Mark Tapsak , Dubravka Markovic
IPC: A61F13/00
CPC classification number: A61B5/14865 , A61B5/14532 , A61L31/10 , A61L31/14 , A61L31/146 , A61L31/16 , A61L2300/00 , B33Y80/00 , G01N33/48707
Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.
-
公开(公告)号：US20050192557A1
公开(公告)日：2005-09-01
申请号：US10789359
申请日：2004-02-26
Applicant: James Brauker , Mark Tapsak , Sean Saint , Apurv Kamath , Paul Neale , Peter Simpson , Michael Mensinger , Dubravka Markovic
Inventor： James Brauker , Mark Tapsak , Sean Saint , Apurv Kamath , Paul Neale , Peter Simpson , Michael Mensinger , Dubravka Markovic
CPC classification number: A61M5/31525 , A61B5/0002 , A61B5/14532 , A61B5/1486 , A61B5/14865 , A61B5/4839 , A61B2560/0443 , A61M5/1723 , A61M11/00 , A61M15/0001 , A61M2005/1726 , A61M2205/18 , A61M2205/3303 , A61M2205/502 , A61M2205/52 , A61M2230/201 , G06F19/00 , G06F19/3468 , G16H20/17 , G16H40/63
Abstract: Abstract of the DisclosureSystems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
Abstract translation: 公开的摘要提供了一种用于集成包括接收器，药物输送装置和任选的单点葡萄糖监测器的连续葡萄糖传感器的系统和方法。 手动集成提供了用户（例如，患者或医生）手动选择数量，类型和/或递送时间的设备之间的物理关联。 设备的半自动化集成包括集成，其中集成组件之间的可操作连接有助于用户（例如患者或医生）在选择，输入，计算或验证葡萄糖值的药物递送量，类型或时间 例如，通过将数据发送到另一个组件，从而减少所需的用户输入量。 设备之间的自动集成包括集成，其中集成组件之间的可操作连接提供对系统的完全控制，而不需要用户交互。
-
公开(公告)号：US20050031689A1
公开(公告)日：2005-02-10
申请号：US10842716
申请日：2004-05-10
Applicant: Mark Shults , James Brauker , Victoria Carr-Brendel , Mark Tapsak , Dubravka Markovic
Inventor： Mark Shults , James Brauker , Victoria Carr-Brendel , Mark Tapsak , Dubravka Markovic
CPC classification number: A61B5/14865 , A61B5/14532 , A61L31/10 , A61L31/14 , A61L31/146 , A61L31/16 , A61L2300/00 , B33Y80/00 , G01N33/48707
Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.
Abstract translation: 一种用于可植入装置的生物界面膜，其包括不可再吸收的固体部分，其具有适于在体内支持组织向内生长的多个相互连接的空腔，以及并入生物界面膜中并适于修饰组织反应的生物活性剂。 可以选择生物活性剂以诱导血管形成和/或预防体内阻隔细胞层形成，并且当与其中溶质被输送穿过装置 - 组织界面的可植入装置一起使用时是有利的。
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.043 seconds)
